-
What does argenx do?
- argenx is a biotechnology company that focuses on developing innovative therapies for patients with severe autoimmune diseases and cancer. The company leverages its proprietary antibody platform to create novel treatments aimed at addressing unmet medical needs. Through its research and development efforts, argenx aims to improve the quality of life for patients worldwide.
-
Company number
-
0818.292.196
-
Location
- Industriepark-Zwijnaarde 7 Gent 9052
-
Founding date
- Founded in 04-09-2009
-
Juridical situation
- Normale toestand
-
Juridical form
- Besloten Vennootschap
-
Type of enterprise
- Rechtspersoon
Very high risk
High risk
Average
Low risk
Very low risk
| Financial ratios | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Equity |
€
3.84B
36.01%
|
€
2.82B
27.04%
|
€
2.22B
87.49%
|
€
1.19B
|
| Turnover |
€
1.22B
142.12%
|
€
505.33M
2829.51%
|
€
17.25M
|
|
| Profit |
€
-386.59M
21.97%
|
€
-495.42M
-61.59%
|
€
-306.58M
40.47%
|
€
-515.00M
|
| EBITDA |
€
535.57M
132.85%
|
€
230.00M
37.45%
|
€
167.33M
208.66%
|
€
-154.00M
|
| Debt |
€
1.15B
102.35%
|
€
569.15M
41.33%
|
€
402.70M
-20.78%
|
€
508.34M
|
| Cash |
€
11.49M
-73.09%
|
€
42.69M
-57.1%
|
€
99.50M
-31.35%
|
€
144.93M
|
| Employees |
408.90
17.5%
|
348.00
22.15%
|
284.90
70.8%
|
166.80
|
Directors
All directorsARGENX SE
Bosstraat 49/A Buggenhout Belgium
Activities according to NACEBEL codes
Activities
VAT Activities
Social Security Activities
Publications 43
All publicationsSimilar companies
Show allFrequently asked questions
The VAT number of argenx is BE0818.292.196.
In 2023, argenx employed 408.90 full-time equivalents (FTE).
argenx was founded in 04-09-2009.
The official address of argenx is Industriepark-Zwijnaarde 7 Gent 9052 .
The juridical form of argenx is Besloten Vennootschap.
The legal situation of argenx is Normale toestand.
The annual revenue of argenx is €1,223,492,063.
argenx is a biotechnology company that focuses on developing innovative therapies for patients with severe autoimmune diseases and cancer. The company leverages its proprietary antibody platform to create novel treatments aimed at addressing unmet medical needs. Through its research and development efforts, argenx aims to improve the quality of life for patients worldwide.
Sources
Ready to start?
Find out the financial situation of potential customers, suppliers or business partners by consulting official information and key figures.
